CN109316533B - 一种清除猪体内毒素的发酵中药复方制剂及其应用 - Google Patents
一种清除猪体内毒素的发酵中药复方制剂及其应用 Download PDFInfo
- Publication number
- CN109316533B CN109316533B CN201811480092.2A CN201811480092A CN109316533B CN 109316533 B CN109316533 B CN 109316533B CN 201811480092 A CN201811480092 A CN 201811480092A CN 109316533 B CN109316533 B CN 109316533B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- compound preparation
- medicine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 239000002158 endotoxin Substances 0.000 title claims abstract description 16
- 229910052901 montmorillonite Inorganic materials 0.000 claims abstract description 15
- 239000001963 growth medium Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 11
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 10
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 10
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 10
- 244000269722 Thea sinensis Species 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims description 43
- 230000004151 fermentation Effects 0.000 claims description 43
- 239000000706 filtrate Substances 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 15
- 241000186000 Bifidobacterium Species 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 241000193171 Clostridium butyricum Species 0.000 claims description 13
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 235000013717 Houttuynia Nutrition 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 abstract description 16
- 239000003053 toxin Substances 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 4
- 239000011707 mineral Substances 0.000 abstract description 4
- 241000282887 Suidae Species 0.000 abstract description 3
- 239000003463 adsorbent Substances 0.000 abstract description 2
- 206010035148 Plague Diseases 0.000 abstract 1
- 241000607479 Yersinia pestis Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 16
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 16
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 16
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 16
- 229940074393 chlorogenic acid Drugs 0.000 description 16
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 16
- 235000001368 chlorogenic acid Nutrition 0.000 description 16
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 16
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 15
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 15
- 108700012359 toxins Proteins 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 11
- 230000000813 microbial effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 241000758794 Asarum Species 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229930183344 ochratoxin Natural products 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Sustainable Development (AREA)
- Birds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种清除猪体内毒素的发酵中药复方制剂,采用下述方法制得:按以下质量份组份:野菊花25‑32份,金银花28‑35份,鱼腥草28‑35份,连翘18‑22份,茶叶25‑35份,甘草12‑20份;提取上述组份制成中药培养基,接种发酵菌发酵,加入纳米蒙脱石90‑110份混合即得。本发明的清除猪体内毒素的发酵中药复方制剂,通过使用清瘟败毒发酵中药、特殊矿物质吸附剂和增强机体抵抗力等复配制剂清除猪体内毒素,达到消除猪亚健康、减少疾病的发生和提高生产性能的目的。
Description
技术领域
本发明属于动物保健品技术领域,具体来说,涉及一种清除猪体内毒素的发酵中药复方制剂及其制备方法和应用。
背景技术
养猪生产中,猪体内往往会蓄积大量的各种毒素,给养猪生产带来巨大的经济损失。而解决猪体内毒素的常用方法一般是使用脱霉剂给饲料脱毒,或者使用某些效果并不十分理想的保肝护肾的方法,这些方法都不足以有效清除猪体内的毒素。
导致猪体内毒素蓄积的主要原因有饲料中存在的严重霉菌毒素(如黄曲霉毒素、赤霉烯酮、呕吐毒素和赭曲霉毒素等),饲料原料中残留的农药,饲料中过剩的蛋白质和脂肪等转化过程中产生的代谢产物和过量的重金属如铜、锌和铁等残留;还有胃肠道长期生存的常住菌(如消化链球菌、韦荣氏球菌、大肠杆菌和肠球菌等)产生的内毒素,链球菌、葡萄球菌等产生的外毒素;病毒毒素;机体代谢产生的生物毒素;使用抗生素等药物做保健和疾病治疗用药,蓄积到体内脏器的药物残留;机体受外界病邪侵袭,防御过程中产生的大量代谢毒素;空气中的有害气体进入体内,蓄积到气管、支气管、肺泡等气管;母猪便秘导致粪便中的毒素重新进入血液等等。正常情况下,猪本身的某些器官(如肝脏、肾脏、消化道、脾脏、淋巴、血液、肺脏和皮肤等)具有一定的解毒能力,但是,当机体解毒器官最大解毒能力都无法解除体内蓄积的过多的毒素时,机体内的毒素将逐步侵害其它脏器,造成机体内脏器官的损伤、产生免疫抑制,影响疫苗免疫和使机体免疫力的下降,导致大量疾病的发生。
发明内容
针对现有养猪生产中体内毒素蓄积的问题,本发明的目的在于提供了一种清除猪体内毒素的发酵中药复方制剂,通过使用清瘟败毒发酵中药、特殊矿物质吸附剂和增强机体抵抗力等复配制剂清除猪体内毒素,达到消除猪亚健康、减少疾病的发生和提高生产性能的目的。
为了实现上述技术目的,本发明提供了一种清除猪体内毒素的发酵中药复方制剂,采用下述方法制得:按以下质量份组份:野菊花25-32份,金银花28-35份,鱼腥草28-35份,连翘18-22份,茶叶25-35份,甘草12-20份;提取上述组份制成中药培养基,接种发酵菌发酵,加入纳米蒙脱石90-110份混合即得。
优选的,按以下质量份组份:野菊花30份,金银花30份,鱼腥草30份,连翘20份,茶叶30份,甘草15份,纳米蒙脱石100份。
优选的,所述提取方法包括如下步骤:
步骤(1),加10倍中药体积水浸泡2-3h后,先用武火加热,待沸腾后再用文火加热l.5h,四层纱布过滤得到初滤液和初级药渣,药渣复煎2次;
步骤(2),加6倍于初级药渣的体积水,煎煮1h,四层纱布过滤,得二级滤液和二级药渣;
步骤(3),加4倍于二级药渣的体积水,煎煮1h,四层纱布过滤,得三级滤液和三级药渣;
将初滤液、二级滤液和三级滤液混合浓缩至浓度为1g/mL后,冷藏备用。
优选的,所述中药培养基配方为:中药提取液96-98%,葡萄糖1.0-2.5%,乳糖1.0-1.5%。
优选的,按中药培养基体积的3.2%接种2.0×109cfu/mL的发酵菌,所述发酵菌包括乳酸菌、丁酸梭菌和双歧杆菌。
更优选的,乳酸菌、丁酸梭菌和双歧杆菌的浓度比为1:0.8-1.0:0.8-1.0;最优选的,乳酸菌、丁酸梭菌和双歧杆菌的浓度比为1:0.8:0.8。
本发明中,微生物发酵菌种(或菌株)的选择非常重要,特别是中药成分的复杂性和多效性对发酵菌种的要求非常严格,需要根据不同的中药组方及活性成分需要,来进行菌种的选择,实施定向发酵。乳酸菌、丁酸梭菌和双歧杆菌的不同菌种配比,其主要活性成分中的绿原酸和蒙花苷的含量都明显增加,当按照1:0.8:0.8的配比时,其主要活性成分蒙花苷和绿原酸的含量最高,增加最明显。在本发明中的中药成分的组方和每位中药中的活性成分,定向性的决定了优势发酵菌为乳酸菌、丁酸梭菌和双歧杆菌。
优选的,所述发酵培养的条件为:pH为5-6.5,温度为36.0-37.5℃,时间为12-14h。
本发明研究发现,当pH值大6.5和小于5时,发酵菌的整体活力下降,有效成分含量增加不明显,且pH值偏离5-6.5越远,效果越差,影响发酵效果越明显;发酵温度偏离最佳发酵温度时,发酵效果会受到影响,发酵温度偏低时发酵时间需延长,发酵温度偏高时,发酵菌新陈代谢加快,死亡率增加,需要不断的补充发酵菌,增加发酵成本,同时影响发酵效果;发酵时间的长短决定于发酵时的pH值和发酵温度,本发明的试验研究发现,当pH 5-6.5、温度36.0-37.5℃时,发酵时间为12-14h的效果最理想,有效成分含量最高。
本发明还提供了所述发酵中药复方制剂的应用,将其用作饲料添加剂,添加量为饲料的0.5-1wt%或5-10kg/吨饲料。
野菊花主要成分为蒙花苷、挥发油和野菊花内酯,能疏散风热、消肿解毒,主要治疗病毒性疾病、咽喉肿痛、风火赤眼和头痛眩晕等病证;配以金银花中重要的生物活性物质绿原酸,能较强的增加抗菌、抗病毒、保肝利胆和清除机体内自由基;再配以鱼腥草的主要成分金丝桃甙、癸酰乙醛和月桂醛等,能增强野菊花的清热解毒、消肿疗疮的作用,同时增加了金银花的抗菌、抗病毒、利尿除湿和排毒功能;茶叶主要成分为茶多酚、儿茶素、胆甾烯酮和咖啡碱等,具有清热解毒、利水通便和增强免疫力作用,能配伍鱼腥草增强其利尿排毒作用,配伍野菊花和金银花能显著增强其清热解毒、抗细菌、抗病毒和增强免疫力的作用。利用甘草中的主要成分甘草甜素、甘草次酸、甘草甙、异甘草甙和黄酮类物质,具有的清热解毒作用和调和诸药的协调作用,以增强配方的整体效果。
本发明的有益效果是:
本产品主要由具有清瘟败毒、吸附毒素,抗病毒、抗细菌和增强机体免疫功能的特效中草药(野菊花、金银花、鱼腥草和连翘)有效成分,经科学配伍而成;并经过微生物的发酵作用,显著提高有效成分的含量,增强疗效。同时,本产品配合使用纳米级蒙脱石粉,进一步增加吸附毒素的功能。
本发明使用具有独特功能的中草药有效成分科学配伍,经筛选微生物菌通过发酵工艺后配合绿色环保的纳米蒙脱石而制成,具有绿色环保、疗效确实且不易产生耐药性等特点。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不限定于本发明。
本发明所有使用菌种均购置于广州微立旺生物科技有限公司。
实施例1:不同配伍制剂发酵前后对主要成分(蒙花苷和绿原酸)的影响
本发明的主要成分含量测定试验中,发明人按照表1中的不同组方进行中药配伍,分组为A-F。每组都按照同样方法进行提取,并对提取物进行发酵,然后使用液相色谱仪进行主要成分蒙花苷和绿原酸的含量测定。
表1不同配伍制剂的组份及含量(按质量份计)
提取方法与发酵试验:按上述表1中的不同组方进行中药配伍,加10倍中药体积水浸泡3h后,先用武火加热,待沸腾后再用文火加热l.5h,四层纱布过滤得到初滤液和初级药渣;加6倍于初级药渣的体积水,煎煮1h,四层过滤,得二级滤液和二级药渣;加4倍于二级药渣的体积水,煎煮1h,四层过滤,得三级滤液和三级药渣;将初滤液、二级滤液和三级滤液混合浓缩,得中药主要成分提取液,相当于1g/mL的浓度。向中药提取液中加入葡萄糖和乳糖制成中药培养基(中药提取液97%、葡萄糖1.8%、乳糖1.2%);高压灭菌冷却后,按中药培养基体积的3.2%接种2.0×109cfu/mL乳酸菌、丁酸梭菌和双歧杆菌(1:0.8:0.8)的发酵菌,在pH为6.5,37℃的温度下培养14小时发酵培养,制得微生物发酵中药制剂,再加入纳米蒙脱石混合即得复方制剂。
每组主要成分的含量测定:使用日本岛津高效液相色谱仪(LC-2010A HT)进行主成分蒙花苷和绿原酸的含量测定,不同配伍制剂组发酵前后主要成分含量见表2和3。试验研究发现,不同的中药组份配伍及是否发酵,对其中的主要活性成分有较明显影响,特别是绿原酸含量明显增加,表现出配伍成分之间的协同作用和发酵的优势。
表2不同配伍制剂主要活性成分含量(发酵前)单位:(%)
表3不同配伍制剂主要活性成分含量(发酵后)单位:(%)
实施例2:不同发酵菌种组合对主要活性组份蒙花苷和绿原酸的含量的影响
按以下质量份组分:野菊花30份,金银花30份,鱼腥草30份,连翘20份,茶叶30份,甘草15份,加10倍中药体积水浸泡3h后,先用武火加热,待沸腾后再用文火加热l.5h,四层纱布过滤得到初滤液和初级药渣;加6倍于初级药渣的体积水,煎煮1h,四层过滤,得二级滤液和二级药渣;加4倍于二级药渣的体积水,煎煮1h,四层过滤,得三级滤液和三级药渣;将初滤液、二级滤液和三级滤液混合浓缩,得中药主要成分提取液,相当于1g/mL的浓度;向上述的中药主要成分提取液,加入葡萄糖和乳糖制成中药培养基(中药提取液97%、葡萄糖1.8%、乳糖1.2%);高压灭菌冷却后,按中药培养基体积的3.2%接种2.0×109cfu/mL的发酵菌(见表4),在pH为6.5,37℃的温度下培养14小时发酵培养,制得微生物发酵中药制剂,再加入纳米蒙脱石100份混合即得复方制剂。
表4不同发酵菌种组合(浓度比)单位:菌/mL
每组主要活性组份的含量测定:使用日本岛津高效液相色谱仪(LC-2010A HT)进行主要活性组份蒙花苷和绿原酸的含量测定,不同发酵菌种组合条件下的蒙花苷和绿原酸的含量见表5。
表5不同发酵菌种组合条件下的蒙花苷和绿原酸的含量单位:(%)
本发明中微生物发酵菌种(或菌株)的选择非常重要,特别是中药成分的复杂性和多效性对发酵菌种的选择非常严格,需要根据不同的中药组方及活性成分需要,来进行菌种的选择,实施定向发酵。所以,菌种的选择和组合决定了试验的成败。本发明的试验研究中发现,E组(枯草芽孢杆菌、灵芝菌和DL菌)和F组(乳酸菌、双歧杆菌和地衣芽孢杆菌)的不同菌种比例组合,其主要活性成分绿原酸和蒙花苷的含量几乎没有增加;C组(丁酸梭菌、双歧杆菌和酵母菌)的不同菌种比例组合,其主要活性成分中的蒙花苷含量有所提高,但绿原酸的含量增加不明显;A组(乳酸菌、灵芝菌和DL菌)和B组(乳酸菌、双歧杆菌和酵母菌)的不同菌种比例组合,其主要活性成分中的绿原酸的含量明显增加,且蒙花苷的含量也有所增加;而D组(乳酸菌、丁酸梭菌和双歧杆菌)的不同菌种比例组合,按照1:0.8:0.8的配比,其主要活性成分绿原酸的含量得到了极大的提升,且蒙花苷的含量也较其它菌种组合增加较多,优势最明显。在本发明中的中药成分的组方和每位中药中的活性成分,定向性的决定了优势发酵菌为乳酸菌、丁酸梭菌和双歧杆菌。
实施例3:本发明复方制剂与本发明中的未加入纳米蒙脱石的单一微生物发酵中药制剂、单一纳米蒙脱石清除母猪体内毒素的对比效果
按以下质量份组分:野菊花30份,金银花30份,鱼腥草30份,连翘20份,茶叶30份,甘草15份,加10倍中药体积水浸泡3h后,先用武火加热,待沸腾后再用文火加热l.5h,四层纱布过滤得到初滤液和初级药渣;加6倍于初级药渣的体积水,煎煮1h,四层过滤,得二级滤液和二级药渣;加4倍于二级药渣的体积水,煎煮1h,四层过滤,得三级滤液和三级药渣;将初滤液、二级滤液和三级滤液混合浓缩,得中药主要成分提取液,相当于1g/mL的浓度;向上述的中药主要成分提取液,加入葡萄糖和乳糖制成中药培养基(中药提取液97%、葡萄糖1.8%、乳糖1.2%);高压灭菌冷却后,按中药培养基体积的3.2%接种2.0×109cfu/mL乳酸菌、丁酸梭菌和双歧杆菌(1:0.8:0.8)的发酵菌,在pH为6.5,37℃的温度下培养14小时发酵培养,制得微生物发酵中药制剂,再加入纳米蒙脱石100份混合即得复方制剂。
试验动物选择某猪场精神状态、食欲和体温等临床表现基本正常,但表现皮毛粗糙、皮肤皮屑多、泪斑和眼粪多、消瘦和生产性能低下等明显毒素蓄积的经产母猪120头,随机分成12组,每组10头,随机对应于表5中的4个组,每组设3个重复,进行试验,复方制剂组按照1%添加于饲料中,纳米蒙脱石组按照0.9%进行拌料饲喂,微生物发酵中药制剂组按照0.1%进行拌料饲喂,连续饲喂20天,观察母猪的临床表现和生产性能指标。清除猪体内毒素的效果以有效率来评价,其效果分为有效和无效,有效包括特明显、明显和较明显,有效率=效果特明显的数量+明显的数量+较明显的数量/每组总数量的百分比。试验结果见表6。
表6本发明产品与常用脱毒产品清除母猪体内毒素的对比效果单位:(头/%)
试验结果表明:本发明复方制剂对母猪体内毒素的清除作用,明显优于单一的矿物质类纳米蒙脱石脱霉剂和单一的微生物发酵中药制剂,进一步说明了本发明中将中药发酵后与矿物质类纳米蒙脱石进行混合使用的优势。
主要原因是本发明中合理使用中药配伍,并进行发酵后,其活性成分显著增强了疏散风热、清热解毒、利尿除湿和排毒功能,同时增强了消炎、抗菌、抗病毒和免疫力等作用;最后配以纳米蒙脱石极强的脱饲料霉菌毒素、内毒素和吸附清除细菌与病毒作用,使本发明产品表现出明显的优势。
Claims (8)
1.一种清除猪体内毒素的发酵中药复方制剂,其特征在于:采用下述方法制得:按以下质量份组份:野菊花25-32份,金银花28-35份,鱼腥草28-35份,连翘18-22份,茶叶25-35份,甘草12-20份;提取以上组份获得中药提取液后制成中药培养基,接种发酵菌发酵后再加入纳米蒙脱石90-110份混合即得;
所述发酵菌包括乳酸菌、丁酸梭菌和双歧杆菌,乳酸菌、丁酸梭菌和双歧杆菌的浓度比为1:0.8-1.0:0.8-1.0。
2.根据权利要求1所述的发酵中药复方制剂,其特征在于:按以下质量份组份:野菊花30份,金银花30份,鱼腥草30份,连翘20份,茶叶30份,甘草15份,纳米蒙脱石100份。
3.根据权利要求1所述的发酵中药复方制剂,其特征在于:提取方法包括如下步骤:
步骤(1),加10倍中药体积水浸泡2-3h后,先用武火加热,待沸腾后再用文火加热l.5h,四层纱布过滤得到初滤液和初级药渣,药渣复煎2次;
步骤(2),加6倍于初级药渣的体积水,煎煮1h,四层纱布过滤,得二级滤液和二级药渣;
步骤(3),加4倍于二级药渣的体积水,煎煮1h,四层纱布过滤,得三级滤液和三级药渣;
将初滤液、二级滤液和三级滤液混合浓缩为浓度为1g/mL后,冷藏备用。
4.根据权利要求1所述的发酵中药复方制剂,其特征在于:中药培养基配方为:中药提取液96-98%,葡萄糖1.0-2.5%,乳糖1.0-1.5%。
5.根据权利要求1所述的发酵中药复方制剂,其特征在于:按中药培养基体积的3.2%接种2.0×109cfu/mL的发酵菌。
6.根据权利要求1所述的发酵中药复方制剂,其特征在于:乳酸菌、丁酸梭菌和双歧杆菌的浓度比为1:0.8:0.8。
7.根据权利要求1所述的发酵中药复方制剂,其特征在于:发酵培养的条件为:pH为5-6.5,温度为36.0-37.5℃,时间为12-14h。
8.权利要求1-7任一项所述的发酵中药复方制剂的应用,其特征在于:将其用于制备饲料添加剂,添加量为饲料的0.5-1wt%或5-10kg/吨饲料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811480092.2A CN109316533B (zh) | 2018-12-05 | 2018-12-05 | 一种清除猪体内毒素的发酵中药复方制剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811480092.2A CN109316533B (zh) | 2018-12-05 | 2018-12-05 | 一种清除猪体内毒素的发酵中药复方制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109316533A CN109316533A (zh) | 2019-02-12 |
CN109316533B true CN109316533B (zh) | 2021-06-15 |
Family
ID=65256604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811480092.2A Active CN109316533B (zh) | 2018-12-05 | 2018-12-05 | 一种清除猪体内毒素的发酵中药复方制剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109316533B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112704158A (zh) * | 2020-09-17 | 2021-04-27 | 安徽志德动物营养科技有限公司 | 一种中药及茶叶的混合发酵型饲料添加剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846674A (zh) * | 2012-08-31 | 2013-01-02 | 郑州后羿制药有限公司 | 一种中药微生态组合物及其制备方法 |
CN105594995A (zh) * | 2016-03-15 | 2016-05-25 | 济南众粮饲料有限公司 | 排毒型功能饲料 |
CN105726661A (zh) * | 2016-03-29 | 2016-07-06 | 郑州赛科药业科技有限公司 | 用于清除畜禽体内毒素的复方制剂及其制备方法 |
CN106173269A (zh) * | 2016-08-02 | 2016-12-07 | 北京慧农生物科技有限公司 | 一种畜禽用饲料脱毒剂及其制备方法与应用 |
-
2018
- 2018-12-05 CN CN201811480092.2A patent/CN109316533B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846674A (zh) * | 2012-08-31 | 2013-01-02 | 郑州后羿制药有限公司 | 一种中药微生态组合物及其制备方法 |
CN105594995A (zh) * | 2016-03-15 | 2016-05-25 | 济南众粮饲料有限公司 | 排毒型功能饲料 |
CN105726661A (zh) * | 2016-03-29 | 2016-07-06 | 郑州赛科药业科技有限公司 | 用于清除畜禽体内毒素的复方制剂及其制备方法 |
CN106173269A (zh) * | 2016-08-02 | 2016-12-07 | 北京慧农生物科技有限公司 | 一种畜禽用饲料脱毒剂及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
蒙脱石在兽医临床上的应用;潘海宁;《温州农业科技》;20080315(第01期);第36页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109316533A (zh) | 2019-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104688895B (zh) | 一种防治肉鸡呼吸道疾病的中药益生菌复合制剂 | |
CN101214311B (zh) | 一种治疗畜禽传染病的复方黄芩注射液及其制备方法 | |
CN102614288A (zh) | 一种防治鸡大肠杆菌疾病的中药微生态制剂及其制备方法 | |
CN101428047A (zh) | 一种石榴皮总酚的制备方法及其应用 | |
Akrayi et al. | Screening in vitro and in vivo the antibacterial activity of Rhus coriaria extract against S. aureus | |
CN102764308A (zh) | 一种防治鱼类细菌性疾病的药物及其制备方法 | |
CN109316533B (zh) | 一种清除猪体内毒素的发酵中药复方制剂及其应用 | |
CN102973690A (zh) | 一种治疗猪肠炎的中草药制剂 | |
CN103127198B (zh) | 治疗仔猪黄白痢的联合用药物 | |
CN102318746A (zh) | 一种用于细菌性畜禽疾病的动物保健品 | |
CN107260774A (zh) | 蜡梅属植物抗致病菌感染的用途 | |
CN106619767A (zh) | 一种治疗奶牛乳房炎的药物组合物及其制备方法和用途 | |
CN105943679A (zh) | 一种家禽用中药益生菌复合制剂及其制备方法 | |
CN102367420A (zh) | 牛饲料用中药益生菌液体培养基、培养方法及饲料添加剂 | |
CN109646546B (zh) | 一种用于防治牲畜腹泻的中药组合物及其制备方法 | |
CN113967243B (zh) | 一种用于防治家禽腹泻的发酵中药制剂及其制备方法 | |
CN104784299B (zh) | 一种含地锦草苦参和黄芩的发酵中药组合物及其制备方法 | |
CN109432287B (zh) | 一种防治家禽气分热盛证的中药口服液及其制备方法 | |
CN107125433A (zh) | 含中药的畜禽饲料添加剂及其制备方法 | |
CN111358853A (zh) | 一种治疗畜禽衣原体病的中草药制剂及其制备与应用 | |
CN110404006A (zh) | 一种治疗鸡坏死性肠炎的药物组合物 | |
CN112023018B (zh) | 一种用于防治家畜腹泻的中药组合物及其制备方法与应用 | |
CN111544570B (zh) | 一种添加抗菌肽的抗病毒制剂及其制备方法 | |
CN111281922B (zh) | 一种用于治疗猪禽腹泻的复方中兽药口服制剂及其制备方法 | |
CN107898876A (zh) | 疗效好的板青颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |